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Abstract
Background: Microsomal transfer protein inhibitors (MTPi) have the potential to be used as a
drug to lower plasma lipids, mainly plasma triglycerides (TG). However, studies with animal models
have indicated that MTPi treatment results in the accumulation of hepatic TG. The purpose of this
study was to evaluate whether JTT-130, a unique MTPi, targeted to the intestine, would effectively
reduce plasma lipids without inducing a fatty liver.
Methods: Male guinea pigs (n = 10 per group) were used for this experiment. Initially all guinea
pigs were fed a hypercholesterolemic diet containing 0.08 g/100 g dietary cholesterol for 3 wk.
After this period, animals were randomly assigned to diets containing 0 (control), 0.0005 or 0.0015
g/100 g of MTPi for 4 wk. A diet containing 0.05 g/100 g of atorvastatin, an HMG-CoA reductase
inhibitor was used as the positive control. At the end of the 7th week, guinea pigs were sacrificed
to assess drug effects on plasma and hepatic lipids, composition of LDL and VLDL, hepatic
cholesterol and lipoprotein metabolism.
Results: Plasma LDL cholesterol and TG were 25 and 30% lower in guinea pigs treated with MTPi
compared to controls (P < 0.05). Atorvastatin had the most pronounced hypolipidemic effects with
a 35% reduction in LDL cholesterol and 40% reduction in TG. JTT-130 did not induce hepatic lipid
accumulation compared to controls. Cholesteryl ester transfer protein (CETP) activity was
reduced in a dose dependent manner by increasing doses of MTPi and guinea pigs treated with
atorvastatin had the lowest CETP activity (P < 0.01). In addition the number of molecules of
cholesteryl ester in LDL and LDL diameter were lower in guinea pigs treated with atorvastatin. In
contrast, hepatic enzymes involved in maintaining cholesterol homeostasis were not affected by
drug treatment.
Conclusion: These results suggest that JTT-130 could have potential clinical applications due to
its plasma lipid lowering effects with no alterations in hepatic lipid concentrations.
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Background

Methods

Microsomal triglyceride transfer protein (MTP) is a resident protein in the lumen of endoplasmic reticulum and
is primarily responsible for transfer of triglycerides (TG)
and other lipids from their site of synthesis in the endoplasmic reticulum into the lumen during the assembly of
very low density lipoprotein (VLDL) [1]. VLDL produced
by the liver are the major source of LDL in plasma and elevated levels of LDL are associated with the development of
atherosclerosis and cardiovascular disease (CVD).
Increased total cholesterol and LDL cholesterol (LDL-C)
are both considered primary risk factors for atherosclerosis [2,3]. To reduce CHD risk factors improvements in diet
and exercise are primary recommendations however
when plasma cholesterol concentrations reach a certain
limit drug intervention is necessary. Statins, which are targeted to 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase and are used extensively, are effective in
lowering LDL-C, and somewhat effective in reducing
plasma TG [4,5]. A number of studies done in the past
have indicated that reduction in LDL-C values by using
statins can significantly reduce the risk of CHD however a
large population of patients still experience a clinical
event [2,4,5]. Therefore, pharmaceutical companies are
continuing to research other drug options to control
hypercholesterolemia with the goal of developing a therapy for treating patients with dyslipidemias. Microsomal
triglyceride transfer protein inhibitor (MTPi) is one such
option. It is believed that blocking MTP will not only
reduce plasma total and LDL cholesterol (LDL-C) but also
plasma VLDL and TG by affecting the packaging and secretion of VLDL and chylomicrons. Certain animal and
human studies [6,7] have shown that the inhibition of
MTP blocks the hepatic secretion of VLDL and the intestinal secretion of chylomicrons. Consequently, this mechanism provides a highly efficacious pharmacological target
for the lowering of LDL-C and reduction of postprandial
lipemia. These effects could afford unprecedented benefit
in the treatment of atherosclerosis and consequent cardiovascular disease. The promise of this therapeutic target
has attracted widespread interest in the pharmaceutical
industry.

Materials
Reagents were obtained from the following sources. JTT130, the MTPi tested was provided by Akros Pharma Inc
(Princeton, NJ). Enzymatic cholesterol and TG kits, cholesterol oxidase, cholesterol esterase and peroxidase were
purchased from Roche-Diagnostics (Indianapolis, IN).
Phospholipid and free cholesterol enzymatic kits were
obtained from Wako Pure Chemical (Osaka, Japan).
Quick-seal ultracentrifuge tubes were from Beckman
(Palo Alto, CA). DL-hydroxy- [3-14C] methyl glutaryl
coenzyme A (1.81 GBq/mmol), DL- [5-3H] mevalonic
acid (370 GBq/mmol), cholesteryl- [1,2,6,7-3H] oleate
(370 GBq/mmol), Aquasol, Liquiflor (toluene concentrate) and [14C] cholesterol were purchased from DuPont
NEN (Boston, MA). Oleoyl- [1-14C] coenzyme A (1.8
GBq/mmol) and DL-3-hydroxy-3-methyl glutaryl coenzyme A were obtained from Amersham (Clearbrook, IL).
Cholesteryl oleate, glucose-6-phosphate, glucose-6-phosphate dehydrogenase, nicotinamide adenine dinucleotide
phosphate (NADP), sodium fluoride, Triton, bovine
serum albumin and sucrose were obtained from Sigma
Chemical (St. Louis, MO). Aluminum and glass silica gel
plates were purchased from EM Science (Gibbstown, NJ).

This research study had a primary goal to evaluate
whether (JTT-130), an MTPi reduces plasma cholesterol
and triglyceride concentrations in male Hartley guinea
pigs. Since JTT-130 is mainly targeted to the intestine,
another main objective of this study was to evaluate
whether this MPTi resulted in less hepatic lipid accumulation compared to other inhibitors [6,7]. Guinea pigs were
used as the animal model for this study because of their
similarities to humans in terms of hepatic cholesterol and
lipoprotein metabolism. Previous studies done in our laboratory report that guinea pig serve as a good model for
evaluating cholesterol lowering drugs [8-10].

Diets
Diets were prepared and pelleted by Research Diets (New
Brunswick, NJ). Isocaloric diets were designed to meet all
the nutritional requirements for guinea pigs. The four
diets had identical composition except for the type and
dose of tested drug as indicated in Table 1. The amount of
cholesterol in the diets was adjusted to be 0.08 g/100 g, an
amount equivalent to 600 mg/day in the human diet [11].
Animals
Forty male guinea pigs (Harlan Sprague-Dawley, Hills),
weighing 250–300 g, were randomly assigned to either a
control, low dose of MTPi (LDI), high dose of MTPi (HDI)
or an atorvastatin (AT) treatment (n = 10/group) for 4
weeks. Initially, all guinea pigs were fed the control diet
for 3 weeks to raise plasma cholesterol concentrations.
Two animals were housed per metal cage in a light cycle
room (light from 0700–1900 h) and had free access to
diets and water. Non-fasted guinea pigs were sacrificed by
heart puncture after isoflurane anesthesia. Blood and livers were harvested for analysis and were stored at -80°C
for further analysis. All animal experiments were conducted in accordance with U.S. Public Health Service/U.S.
Department of Agriculture guidelines. Experimental protocols were approved by the University of Connecticut
Institutional Care and Use Committee.
Lipoprotein isolation
Plasma samples were collected from blood obtained by
heart puncture from guinea pigs under anesthesia. A
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Table 1: Composition of Control, low dose of the inhibitor (LDI), high dose of the inhibitor (HDI) and atorvastatin diets

Components
Soybean protein
Methionine
Sucrose
Corn Starch
Fat mix1
Cellulose
Guar gum
Mineral Mix2
Vitamin Mix2
Cholesterol
JTT-130
Statin

Control %

LDI %

HDI %

Atorvastatin %

22.5
0.5
25
15
15.1
10
2.5
8.2
1.1
0.08
0
0

22.5
0.5
25
15
15.1
10
2.5
8.2
1.1
0.08
0.0005
0

22.5
0.5
25
15
15.1
10
2.5
8.2
1.1
0.08
0.0015
0

22.5
0.5
25
15
15.1
10
2.5
8.2
1.1
0.08
0
0.05

1 Fat

mix for the diet contains olive oil-palm kernel oil-safflower oil (1:2:1.8), high in lauric and myristic acids.
and vitamin mix adjusted to meet NRC requirements for guinea pigs. Detailed composition of the vitamin and mineral mix has been
reported elsewhere (Fernandez et al. 1992b).
2 Mineral

preservation cocktail of aprotonin, phenyl methyl sulfonyl fluoride and sodium azide was added to plasma samples to minimize changes in lipoprotein composition
during isolation. Plasma was aliquoted for LCAT and
CETP determinations, plasma lipid analysis and lipoprotein isolation.
Lipoproteins were isolated by sequential ultracentrifugation [12] in a LE-80K ultracentrifuge (Beckman Instruments, Palo Alto, CA). VLDL was isolated at d = 1.006 kg/
L at 125,000 g at 15°C for 19 h in a Ti-50 rotor. LDL was
isolated at d = 1.019-1.09 kg/L in quick-seal tubes at 15°C
for 3 h at 200,000 g in a vertical Ti-65 rotor [13]. LDL samples were dialyzed in 0.9 g/L sodium chloride-0.1 g/L ethylene diamine tetra acetic acid (EDTA), pH 7.2, for 12 h
and stored at 4°C for further analysis.
Plasma and hepatic lipids
Plasma samples were analyzed for cholesterol and TG by
enzymatic methods [14]. Hepatic total and free cholesterol and TG were determined according to the method by
Carr et al. [15] following extraction of hepatic lipids with
chloroform-methanol 2:1. Cholesteryl ester concentrations were calculated by subtracting free from total
cholesterol.
Lipoprotein characterization
VLDL and LDL composition was calculated by determining free and esterified cholesterol [14], protein by a modified Lowry method [16], and TG and phospholipids by
enzymatic kits. VLDL apo B was selectively precipitated
with isopropanol [17]. The number of constituent molecules of LDL was calculated on the basis of one apo B per
particle with a molecular mass of 412000 kD[18]. The
molecular weights were 885.4, 386.6, 645 and 734 for TG,
free and esterified cholesterol, and phospholipids, respec-

tively [19]. LDL diameters were calculated according to
Van Heek et al [20]. HDL cholesterol was also determined
according to Warnick et al, with a modification, which
consisted of using 2 mol/L MgCl2 for precipitation of apoB containing lipoproteins [13].
Lecithin Cholesterol Acyltransferase (LCAT) and
Cholesterol Ester Transfer Protein (CETP) determinations
in plasma
LCAT and CETP activities were determined according to
Ogawa & Fielding [21]. Physiological CETP activity was
determined without inhibiting LCAT activity by measuring the mass transfer of cholesterol ester between HDL
and apo B containing lipoproteins. Samples were incubated at 37°C for 6 h in a shaking water bath and total
and free plasma cholesterol and HDL cholesterol were
measured. LCAT activity was determined by mass analysis
of the decrease in plasma free cholesterol between 0 and
6 h at 37°C. Assays were carried out concurrently with
measurements of CETP. Both of these methods have been
well-standardized for guinea pig plasma [22].
Hepatic microsome isolation
Hepatic microsomes were isolated as described previously
[8]. Briefly a microsomal fraction was isolated by two 25min centrifugations at 10,000 g (JA-20 rotor, J2-21) followed by ultracentrifugation at 100,000 g in a Ti-50 rotor
at 4°C for 1 hour. Microsomes were resuspended in the
homogenization buffer and centrifuged for an additional
hour at 100,000 g. After centrifugation, microsomal pellets were homogenized and stored at -70°C.
Hepatic HMG-CoA reductase assay
The activity of microsomal HMG-CoA reductase (E.C.
1.1.1.34) was measured in hepatic microsomes as
described by Shapiro et al. [23]. HMG-CoA reductase
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activity was expressed as pmol of [14C] mevalonate produced per min per mg microsomal protein. Recoveries of
[3H] mevalonate ranged from 60–90%.

600
500

W e ig h t (g )

Hepatic Acyl CoA Cholesteryl Acyltransferase (ACAT)
activity
Hepatic ACAT (E.C. 2.3.1.26) activity was measured by
the incorporation of [14C] oleoyl CoA in cholesteryl ester
in hepatic microsomes by preincubating 0.8–1 mg of
microsomal protein per assay with 84 g/L albumin and
buffer for microsomal isolation [24]. Recoveries of [3H]
cholesteryl oleate were between 70–90%.
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Hepatic cholesterol 7α-hydroxylase activity
Cholesterol 7α-hydroxylase (E.C. 1.14.13.7) activity was
measured according to the method modified by Jelinik et
al [25]. [14C] cholesterol was used as a substrate and delivered as cholesterol-phosphatidylcholine liposomes (1:8
by weight) prepared by sonication. An NADPH-regenerating system (glucose-6-phosphate dehydrogenase, NADP,
and glucose-6-phosphate) was included in the assay as a
source of NADPH.

Figure
Weight
high
dose
1
gain
of of
JTT-130
guineaand
pigsatorvastatin
treated with control, low dose,
Weight gain of guinea pigs treated with control, low dose,
high dose of JTT-130 and atorvastatin.

Statistical analysis
One-way analysis of variance (ANOVA) (SSPS for Windows version 12) was used to evaluate significant differences among groups in regards to plasma and hepatic
lipids, LDL composition, hepatic enzyme activities and
LCAT and CETP activities. The LSD post hoc test was used
to evaluate the differences among groups. Data are presented as the mean ± SD. Differences were considered significant at P < 0.05.

The changes in plasma TC values were mostly due to
decreases in the cholesterol carried by LDL. LDL-C was
also significantly decreased (24.7% & 26.9%) by the MTPi
diets tested. There were no major differences between
these two doses for plasma lipid parameters except for
VLDL-C, which were significantly higher when compared
to the low dose of the drug. No significant differences
were observed for HDL-C values with MTPi or with AT
(Table 2).

Results

LDL size and composition
No significant effect of MTPi on the number of CE molecules or on the size of LDL particle was found with any of
the two doses tested as compared to their control counterparts (Table 3). AT treatment reduced the number of esterified cholesterol molecules (45%) as well as decreased the
size of LDL particle (30%) (Table 3).

Plasma lipids and lipoproteins
No difference in weight gain overtime was observed in
guinea pigs fed the different test diets (Fig 1), indicating
that animals consumed comparable amounts of their
respective test diets. After feeding the test diets for a period
of four weeks, blood was isolated and plasma was analyzed for cholesterol and TG concentrations. The two
doses of MTPi evaluated, low dose (LDI) and high dose
(HDI) decreased plasma total cholesterol values significantly by 19.2% (P < 0.01) as compared to the control animals (Table 2). There was no significant difference
between the two doses of MTPi tested. Atorvastatin, which
was used as a positive control, led to a significantly robust
decrease in plasma total cholesterol values of 46%, which
was significantly different (P < 0.01) from the two MTPi
doses used. Plasma TG values were also significantly lower
in LDI (50.8%) and HDI (45.3%) when compared to their
control counterparts whereas atorvastatin (AT) treatment
resulted in the maximum decrease of plasma TG (Table
2).

Time (weeks)

LCAT and CETP activities
Table 3 also summarizes the activities of these two proteins, which play a major role in the intravascular processing of plasma cholesterol. There were no significant
differences in LCAT activity when comparing MTPi or statin groups to the control group. However, HDI decreased
the activity of CETP, which was comparable to the atorvastatin treated group (P < 0.01).
Hepatic lipids and enzymes
No significant changes were found in hepatic total cholesterol, free cholesterol, cholesteyl ester or TG values in any
of the four treatments (Table 4). Results suggest that MTPi
did not lead to lipid accumulation in the liver, as there
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Table 2: Plasma total cholesterol (TC), triglycerides (TG), VLDL-C, LDL-C and HDL-C of guinea pigs fed a control diet, low dose MTPi
(LDI), high dose MTPi (HDI) or atorvastatin

Diets

Control (10)
LDI (10)
HDI (9)
Atorvastatin (9)

TC

TG

VLDL-C

146.9 ± 42.2a
116.9 ± 29.7b
116.1 ± 23.3b
76.5 ± 29.8c

135.8 ± 118.9a
66.7 ± 29.6b
74.3 ± 31.7b
49.4 ± 32.2c

(mg/dL)
8.1 ± 5.5ab
3.7 ± 3.0a
9.0 ± 8.6b
2.9 ± 2.6a

LDL-C

HDL-C

123.9 ± 43.5a
93.3 ± 26.2b
90.5 ± 28.8b
59.4 ± 29.3c

13.6 ± 4.5a
18.5 ± 8.0a
15.6 ± 7.1a
14.1 ± 5.6a

1Data are presented as mean ± SD for the number of guinea pigs indicated in parenthesis. Numbers in a column with different superscripts are
considered significantly different (P < 0.01) as determined by one way ANOVA and LSD as a post-hoc test

Table 3: Number of molecules of cholesteryl ester (CE), LDL diameter and LCAT and CETP activities of guinea pigs fed a control diet,
low dose MTPi (LDI), high dose MTPi (HDI) or atorvastatin.

Diets

CE molecules

LDL diameter

LCAT

Control (n = 10)
LDI (n= 10)
HDI (n = 9)
Atorvastatin (n = 9)

1993 ± 422a
2072 ± 536a
2026 ± 132.5a
1080 ± 1092b

nanometers
16.47 ± 3.63a
16.67 ± 3.05a
16.58 ± 7.85a
11.52 ± 2.69b

19.6 ± 11.0a
14.4 ± 6.4a
14.6 ± 8.5a
13.4 ± 10.9a

CETP
(pmol/min.mg)
36.1 ± 12.5a
31.0 ± 21.1a
19.4 ± 13.0ab
12.8 ± 4.2b

1Data are presented as mean ± SD for the number of guinea pigs indicated in parenthesis. Numbers in a column with different superscripts are
considered significantly different (P < 0.01) as determined by one way ANOVA and LSD as post hoc test.

Table 4: Hepatic total cholesterol (TC), free cholesterol (FC) cholesteryl ester (CE) and TG of guinea pigs fed a control diet, low dose
MTPi (LDI), high dose MTPi (HDI) or atorvastatin1.

Diets

TC

FC

1.20 ± 0.53
1.47 ± 0.40
1.42 ± 0.66
1.71 ± 0.76

1.00 ± 0.44
1.24 ± 0.35
0.98 ± 0.39
1.31 ± 0.56

CE

TG

0.20 ± 0.23
0.23 ± 0.11
0.44 ± 0.58
0.40 ± 0.39

16.2 ± 2.8
13.9 ± 9.4
13.5 ± 7.8
18.8 ± 10.8

(mg/g)
Control (n = 10)
LDI (n = 10)
HDI (n = 9)
Atorvastatin (n = 9)
1Data

are presented as mean ± SD for n = the number of guinea pigs indicated in parenthesis.

was no significant difference between the two doses of
MTPi tested with control or with atorvastatin group. Similarly no significant changes were observed in any of the
three regulatory hepatic enzymes involved, namely CYP7,
ACAT and HMG-CoA Reductase (Table 5).

Discussion
In this study we were able to demonstrate that JTT-130,
the MTPi tested has the potential to decrease the prime
risk factors of cardiovascular disease, namely plasma TG
and LDL-C concentrations in guinea pigs. The novelty of
the drug tested is that there was no significant
accumulation of lipid in the liver as seen in some other
studies done with other MTPi [26,27].

Drug treatment and hepatic lipids
Previous studies evaluating MTPi have shown increase in
the lipid content of the liver [7,26,27]. Chandler et al [7]
treated Hep-G2 cells with CP-346086, another MTPi, for a
period of two weeks. They reported that in addition to
decreasing plasma TC, LDL-C, VLDL-C and TG values, this
treatment also increased hepatic and intestinal TG when
the MTPi was administered with food and when it was
dosed away from meals, only hepatic TG were influenced.
In contrast, the major finding of this study is that the MTPi
tested did not lead to any fat accumulation in the liver as
confirmed by no significant changes found in the hepatic
lipid content as compared to their control counterparts.
The main reason for these differences between MTPi could
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Table 5: Hepatic HMG-CoA reductase, ACAT and cholesterol 7α-hydroxylase activities (CYP7) guinea pigs fed a control diet, low dose
MTPi (LDI), high dose MTPi (HDI) or atorvastatin1

Diets

Control
LDI
HDI
Atorvastatin
1Data

HMG-CoA Reductase

ACAT

CYP7

1.8 ± 0.8
2.7 ± 0.8
2.5 ± 1.4
3.4 ± 2.9

(pmol/min.mg)
0.8 ± 0.4
2.2 ± 0.9
3.5 ± 2.4
4.4 ± 3.1

1.7 ± 1.8
1.2 ± 0.5
0.6 ± 0.7
0.7 ± 0.4

are presented as mean ± SD for n = 3–7 guinea pigs per group.

be that the main target of JTT-130 was the intestine.
Because of this, we speculate that due to MTP inhibition,
less TG were transferred to the chylomicron particle being
packaged in the intestine. As a result a lower concentration of TG was taken up by the hepatocytes through the
chylomicron remnant. Thus the VLDL particles secreted
from the liver had lower concentrations of TG molecules
due to the major inhibitory effect of the MTPi in the intestine. Because there were no significant changes in hepatic
cholesterol concentrations, we did not find any significant
differences in hepatic enzyme activities. Similar to the
study by Conde et al. [9] in atorvastatin treated guinea
pigs with 0.015% atorvastatin, there were no significant
differences in hepatic cholesterol concentrations when
compared with a control group. However, significant differences in hepatic esterified cholesterol were observed
when guinea pigs were treated with a higher dose of the
statin (0.05%) [9].
Drug treatment and plasma lipids and lipoproteins
Abetalipoproteinemia, a genetic disorder characterized by
low plasma cholesterol and TG levels, is caused by a functional deficiency of MTP. Absence of lipid transfer activity
in the microsomes of abetalipoproteinemia patients
established its pivotal function in lipoprotein assembly[1]. This finding led to the suggestion that MTP inhibition could be used as a possible lipid lowering therapy.
Further evidence was obtained from a cell culture study in
which researchers [28] proved that MTP is limiting in the
production of apo B containing lipoproteins. Another
study [6] further confirmed this finding using heterozygous MTP knockout mice which had 20% less plasma
total cholesterol levels compared to wild type mice fed
high fat diets; however, they did not find any significant
differences in plasma TG concentrations. In our study, we
have demonstrated that animals treated with MTPi had
not only lower plasma TC and LDL-C but also significant
reductions in plasma TG. It is possible that the VLDL particle secreted by the liver was more readily catabolized and
therefore there was less conversion to LDL, which contributed to the hypocholesterolemic effects of the MTPi.
Conde et al. [9] demonstrated that there was a significant

reduction in plasma TG in guinea pigs treated with atorvastatin when compared to controls. This was partly
explained by lower secretion of VLDL particles and by
increases in the LDL receptor [9], which could have contributed to the faster removal of VLDL particles. A similar
mechanism may have taken place with the MTPi. By
blocking MTP, JTT-130 reduced the secretion of VLDL particles, and therefore, the formation of LDL in the plasma.
There was a dose response in CETP activity with JTT-130,
and in addition, guinea pigs treated with atorvastatin
exhibited decreased activity of this transfer protein. The
main function of CETP is to contribute to the reverse cholesterol pathway by transferring cholesteryl ester from
HDL to the apo B containing lipoproteins [29]. However,
this action prolongs the residence time of CE in LDL and
increases the possibility of its deposition in the arterial
wall. Thus lower CETP activity has been associated with
decreased atherogenesis in animal studies [30]. Therefore
the lowering of CETP activity by drug treatment can be
considered beneficial.
Results from this study indicate that JTT-130 has the
potential to reduce the primary risk factors for coronary
heart disease. While these results are quite promising,
more studies are needed to clarify the possibility of
adverse effects including steatorhea, fat malabsorption
and fat-soluble vitamin absorption. Although the lipid
lowering effects were not as pronounced as those
observed with atorvastain, the doses of MTPi used in the
current study were lower than the doses of atorvastatin. It
is possible that using JTT-130 in combination with statins
could reduce the wide array of adverse effects associated
with reductase inhibitors [31]. This study also demonstrates that MTP inhibitor which is mainly targeted
towards the intestine may open a new avenue for treatment of hyperlipidemic patients who are at high risk for
cardiovascular diseases.

List of abbreviations used
ACAT: acyl CoA cholesteryl acyl transferase; AT: atorvastatin; CETP: cholesterol ester transfer protein; CHD: coro-
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HDi: high dose of the inhibitor; HDL-C: HDL cholesterol;
HMG-CoA; 3-hydroxy-3methyl glutaryl Conezyme A;
LCAT: lecithin cholesterol acyltransferase; LDi: low dose
of the inhibitor; LDL-C: LDL cholesterol; MTP: microsomal transfer protein; MTPi: microsomal transfer protein
inhibitor; NADP: nicotinamide adenenine dinucleotide
phosphate; TG: triglycerides; VLDL: very low density
lipoprotein.
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